0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Axial Spondyloarthritis Medications Market Research Report 2024
Published Date: June 2024
|
Report Code: QYRE-Auto-3K17681
Home | Market Reports | Health| Health Conditions| Arthritis
Global Axial Spondyloarthritis Medications Market Research Report 2024
BUY CHAPTERS

Global Axial Spondyloarthritis Medications Market Research Report 2024

Code: QYRE-Auto-3K17681
Report
June 2024
Pages:98
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Axial Spondyloarthritis Medications Market

Axial spondyloarthritis (AxSpa) is a chronic inflammatory disease that primarily affects the axial skeleton (joints of the spine, chest, and pelvis). Main symptoms include back pain, fatigue, joint pain, heel pain, sleep disturbances, and abdominal pain. AxSpa symptoms vary from person to person, but for many people, the main symptom is pain that starts gradually in the lower back and hips, especially after a period of inactivity, such as sleep.
The global Axial Spondyloarthritis Medications market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Axial Spondyloarthritis Medications is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Axial Spondyloarthritis Medications is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Axial Spondyloarthritis Medications include Bayer, Novacap, Abbott, Pfizer, Johnson & Johnson, Cigna, Geri-Care Pharmaceuticals, Perrigo Company, Kopran, Merck Sharp & Dohme, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Axial Spondyloarthritis Medications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Axial Spondyloarthritis Medications.
The Axial Spondyloarthritis Medications market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Axial Spondyloarthritis Medications market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Axial Spondyloarthritis Medications manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Axial Spondyloarthritis Medications Market Report

Report Metric Details
Report Name Axial Spondyloarthritis Medications Market
Segment by Type
  • Injection
  • Oral
Segment by Application
  • Hospital
  • Clinic
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bayer, Novacap, Abbott, Pfizer, Johnson & Johnson, Cigna, Geri-Care Pharmaceuticals, Perrigo Company, Kopran, Merck Sharp & Dohme, Sun Pharmaceutical Industries, GlaxoSmithKline, Reddy Pharmaceuticals, Verywell, UCB, Novartis, Eli Lilly and Co., AstraZeneca, DICE Therapeutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Axial Spondyloarthritis Medications manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Axial Spondyloarthritis Medications in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Axial Spondyloarthritis Medications Market report?

Ans: The main players in the Axial Spondyloarthritis Medications Market are Bayer, Novacap, Abbott, Pfizer, Johnson & Johnson, Cigna, Geri-Care Pharmaceuticals, Perrigo Company, Kopran, Merck Sharp & Dohme, Sun Pharmaceutical Industries, GlaxoSmithKline, Reddy Pharmaceuticals, Verywell, UCB, Novartis, Eli Lilly and Co., AstraZeneca, DICE Therapeutics

What are the Application segmentation covered in the Axial Spondyloarthritis Medications Market report?

Ans: The Applications covered in the Axial Spondyloarthritis Medications Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Axial Spondyloarthritis Medications Market report?

Ans: The Types covered in the Axial Spondyloarthritis Medications Market report are Injection, Oral

1 Axial Spondyloarthritis Medications Market Overview
1.1 Product Definition
1.2 Axial Spondyloarthritis Medications by Type
1.2.1 Global Axial Spondyloarthritis Medications Market Value Comparison by Type (2024-2030)
1.2.2 Injection
1.2.3 Oral
1.3 Axial Spondyloarthritis Medications by Application
1.3.1 Global Axial Spondyloarthritis Medications Market Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Axial Spondyloarthritis Medications Market Size Estimates and Forecasts
1.4.1 Global Axial Spondyloarthritis Medications Revenue 2019-2030
1.4.2 Global Axial Spondyloarthritis Medications Sales 2019-2030
1.4.3 Global Axial Spondyloarthritis Medications Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Axial Spondyloarthritis Medications Market Competition by Manufacturers
2.1 Global Axial Spondyloarthritis Medications Sales Market Share by Manufacturers (2019-2024)
2.2 Global Axial Spondyloarthritis Medications Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Axial Spondyloarthritis Medications Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Axial Spondyloarthritis Medications, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Axial Spondyloarthritis Medications, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Axial Spondyloarthritis Medications, Product Type & Application
2.7 Global Key Manufacturers of Axial Spondyloarthritis Medications, Date of Enter into This Industry
2.8 Global Axial Spondyloarthritis Medications Market Competitive Situation and Trends
2.8.1 Global Axial Spondyloarthritis Medications Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Axial Spondyloarthritis Medications Players Market Share by Revenue
2.8.3 Global Axial Spondyloarthritis Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Axial Spondyloarthritis Medications Market Scenario by Region
3.1 Global Axial Spondyloarthritis Medications Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Axial Spondyloarthritis Medications Sales by Region: 2019-2030
3.2.1 Global Axial Spondyloarthritis Medications Sales by Region: 2019-2024
3.2.2 Global Axial Spondyloarthritis Medications Sales by Region: 2025-2030
3.3 Global Axial Spondyloarthritis Medications Revenue by Region: 2019-2030
3.3.1 Global Axial Spondyloarthritis Medications Revenue by Region: 2019-2024
3.3.2 Global Axial Spondyloarthritis Medications Revenue by Region: 2025-2030
3.4 North America Axial Spondyloarthritis Medications Market Facts & Figures by Country
3.4.1 North America Axial Spondyloarthritis Medications Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Axial Spondyloarthritis Medications Sales by Country (2019-2030)
3.4.3 North America Axial Spondyloarthritis Medications Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Axial Spondyloarthritis Medications Market Facts & Figures by Country
3.5.1 Europe Axial Spondyloarthritis Medications Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Axial Spondyloarthritis Medications Sales by Country (2019-2030)
3.5.3 Europe Axial Spondyloarthritis Medications Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Axial Spondyloarthritis Medications Market Facts & Figures by Region
3.6.1 Asia Pacific Axial Spondyloarthritis Medications Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Axial Spondyloarthritis Medications Sales by Region (2019-2030)
3.6.3 Asia Pacific Axial Spondyloarthritis Medications Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Axial Spondyloarthritis Medications Market Facts & Figures by Country
3.7.1 Latin America Axial Spondyloarthritis Medications Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Axial Spondyloarthritis Medications Sales by Country (2019-2030)
3.7.3 Latin America Axial Spondyloarthritis Medications Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Axial Spondyloarthritis Medications Market Facts & Figures by Country
3.8.1 Middle East and Africa Axial Spondyloarthritis Medications Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Axial Spondyloarthritis Medications Sales by Country (2019-2030)
3.8.3 Middle East and Africa Axial Spondyloarthritis Medications Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Axial Spondyloarthritis Medications Sales by Type (2019-2030)
4.1.1 Global Axial Spondyloarthritis Medications Sales by Type (2019-2024)
4.1.2 Global Axial Spondyloarthritis Medications Sales by Type (2025-2030)
4.1.3 Global Axial Spondyloarthritis Medications Sales Market Share by Type (2019-2030)
4.2 Global Axial Spondyloarthritis Medications Revenue by Type (2019-2030)
4.2.1 Global Axial Spondyloarthritis Medications Revenue by Type (2019-2024)
4.2.2 Global Axial Spondyloarthritis Medications Revenue by Type (2025-2030)
4.2.3 Global Axial Spondyloarthritis Medications Revenue Market Share by Type (2019-2030)
4.3 Global Axial Spondyloarthritis Medications Price by Type (2019-2030)
5 Segment by Application
5.1 Global Axial Spondyloarthritis Medications Sales by Application (2019-2030)
5.1.1 Global Axial Spondyloarthritis Medications Sales by Application (2019-2024)
5.1.2 Global Axial Spondyloarthritis Medications Sales by Application (2025-2030)
5.1.3 Global Axial Spondyloarthritis Medications Sales Market Share by Application (2019-2030)
5.2 Global Axial Spondyloarthritis Medications Revenue by Application (2019-2030)
5.2.1 Global Axial Spondyloarthritis Medications Revenue by Application (2019-2024)
5.2.2 Global Axial Spondyloarthritis Medications Revenue by Application (2025-2030)
5.2.3 Global Axial Spondyloarthritis Medications Revenue Market Share by Application (2019-2030)
5.3 Global Axial Spondyloarthritis Medications Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer Axial Spondyloarthritis Medications Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Novacap
6.2.1 Novacap Company Information
6.2.2 Novacap Description and Business Overview
6.2.3 Novacap Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novacap Axial Spondyloarthritis Medications Product Portfolio
6.2.5 Novacap Recent Developments/Updates
6.3 Abbott
6.3.1 Abbott Company Information
6.3.2 Abbott Description and Business Overview
6.3.3 Abbott Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Abbott Axial Spondyloarthritis Medications Product Portfolio
6.3.5 Abbott Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Axial Spondyloarthritis Medications Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Company Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Johnson & Johnson Axial Spondyloarthritis Medications Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Cigna
6.6.1 Cigna Company Information
6.6.2 Cigna Description and Business Overview
6.6.3 Cigna Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Cigna Axial Spondyloarthritis Medications Product Portfolio
6.6.5 Cigna Recent Developments/Updates
6.7 Geri-Care Pharmaceuticals
6.7.1 Geri-Care Pharmaceuticals Company Information
6.7.2 Geri-Care Pharmaceuticals Description and Business Overview
6.7.3 Geri-Care Pharmaceuticals Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Geri-Care Pharmaceuticals Axial Spondyloarthritis Medications Product Portfolio
6.7.5 Geri-Care Pharmaceuticals Recent Developments/Updates
6.8 Perrigo Company
6.8.1 Perrigo Company Company Information
6.8.2 Perrigo Company Description and Business Overview
6.8.3 Perrigo Company Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Perrigo Company Axial Spondyloarthritis Medications Product Portfolio
6.8.5 Perrigo Company Recent Developments/Updates
6.9 Kopran
6.9.1 Kopran Company Information
6.9.2 Kopran Description and Business Overview
6.9.3 Kopran Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Kopran Axial Spondyloarthritis Medications Product Portfolio
6.9.5 Kopran Recent Developments/Updates
6.10 Merck Sharp & Dohme
6.10.1 Merck Sharp & Dohme Company Information
6.10.2 Merck Sharp & Dohme Description and Business Overview
6.10.3 Merck Sharp & Dohme Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Merck Sharp & Dohme Axial Spondyloarthritis Medications Product Portfolio
6.10.5 Merck Sharp & Dohme Recent Developments/Updates
6.11 Sun Pharmaceutical Industries
6.11.1 Sun Pharmaceutical Industries Company Information
6.11.2 Sun Pharmaceutical Industries Description and Business Overview
6.11.3 Sun Pharmaceutical Industries Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Sun Pharmaceutical Industries Axial Spondyloarthritis Medications Product Portfolio
6.11.5 Sun Pharmaceutical Industries Recent Developments/Updates
6.12 GlaxoSmithKline
6.12.1 GlaxoSmithKline Company Information
6.12.2 GlaxoSmithKline Description and Business Overview
6.12.3 GlaxoSmithKline Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.12.4 GlaxoSmithKline Axial Spondyloarthritis Medications Product Portfolio
6.12.5 GlaxoSmithKline Recent Developments/Updates
6.13 Reddy Pharmaceuticals
6.13.1 Reddy Pharmaceuticals Company Information
6.13.2 Reddy Pharmaceuticals Description and Business Overview
6.13.3 Reddy Pharmaceuticals Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Reddy Pharmaceuticals Axial Spondyloarthritis Medications Product Portfolio
6.13.5 Reddy Pharmaceuticals Recent Developments/Updates
6.14 Verywell
6.14.1 Verywell Company Information
6.14.2 Verywell Description and Business Overview
6.14.3 Verywell Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Verywell Axial Spondyloarthritis Medications Product Portfolio
6.14.5 Verywell Recent Developments/Updates
6.15 UCB
6.15.1 UCB Company Information
6.15.2 UCB Description and Business Overview
6.15.3 UCB Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.15.4 UCB Axial Spondyloarthritis Medications Product Portfolio
6.15.5 UCB Recent Developments/Updates
6.16 Novartis
6.16.1 Novartis Company Information
6.16.2 Novartis Description and Business Overview
6.16.3 Novartis Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Novartis Axial Spondyloarthritis Medications Product Portfolio
6.16.5 Novartis Recent Developments/Updates
6.17 Eli Lilly and Co.
6.17.1 Eli Lilly and Co. Company Information
6.17.2 Eli Lilly and Co. Description and Business Overview
6.17.3 Eli Lilly and Co. Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Eli Lilly and Co. Axial Spondyloarthritis Medications Product Portfolio
6.17.5 Eli Lilly and Co. Recent Developments/Updates
6.18 AstraZeneca
6.18.1 AstraZeneca Company Information
6.18.2 AstraZeneca Description and Business Overview
6.18.3 AstraZeneca Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.18.4 AstraZeneca Axial Spondyloarthritis Medications Product Portfolio
6.18.5 AstraZeneca Recent Developments/Updates
6.19 DICE Therapeutics
6.19.1 DICE Therapeutics Company Information
6.19.2 DICE Therapeutics Description and Business Overview
6.19.3 DICE Therapeutics Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2019-2024)
6.19.4 DICE Therapeutics Axial Spondyloarthritis Medications Product Portfolio
6.19.5 DICE Therapeutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Axial Spondyloarthritis Medications Industry Chain Analysis
7.2 Axial Spondyloarthritis Medications Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Axial Spondyloarthritis Medications Production Mode & Process
7.4 Axial Spondyloarthritis Medications Sales and Marketing
7.4.1 Axial Spondyloarthritis Medications Sales Channels
7.4.2 Axial Spondyloarthritis Medications Distributors
7.5 Axial Spondyloarthritis Medications Customers
8 Axial Spondyloarthritis Medications Market Dynamics
8.1 Axial Spondyloarthritis Medications Industry Trends
8.2 Axial Spondyloarthritis Medications Market Drivers
8.3 Axial Spondyloarthritis Medications Market Challenges
8.4 Axial Spondyloarthritis Medications Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Axial Spondyloarthritis Medications Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Axial Spondyloarthritis Medications Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Axial Spondyloarthritis Medications Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Axial Spondyloarthritis Medications Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Axial Spondyloarthritis Medications Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Axial Spondyloarthritis Medications Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Axial Spondyloarthritis Medications Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Axial Spondyloarthritis Medications Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Axial Spondyloarthritis Medications, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Axial Spondyloarthritis Medications, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Axial Spondyloarthritis Medications, Product Type & Application
 Table 12. Global Key Manufacturers of Axial Spondyloarthritis Medications, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Axial Spondyloarthritis Medications by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Axial Spondyloarthritis Medications as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Axial Spondyloarthritis Medications Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Axial Spondyloarthritis Medications Sales by Region (2019-2024) & (K Units)
 Table 18. Global Axial Spondyloarthritis Medications Sales Market Share by Region (2019-2024)
 Table 19. Global Axial Spondyloarthritis Medications Sales by Region (2025-2030) & (K Units)
 Table 20. Global Axial Spondyloarthritis Medications Sales Market Share by Region (2025-2030)
 Table 21. Global Axial Spondyloarthritis Medications Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Axial Spondyloarthritis Medications Revenue Market Share by Region (2019-2024)
 Table 23. Global Axial Spondyloarthritis Medications Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Axial Spondyloarthritis Medications Revenue Market Share by Region (2025-2030)
 Table 25. North America Axial Spondyloarthritis Medications Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Axial Spondyloarthritis Medications Sales by Country (2019-2024) & (K Units)
 Table 27. North America Axial Spondyloarthritis Medications Sales by Country (2025-2030) & (K Units)
 Table 28. North America Axial Spondyloarthritis Medications Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Axial Spondyloarthritis Medications Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Axial Spondyloarthritis Medications Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Axial Spondyloarthritis Medications Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Axial Spondyloarthritis Medications Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Axial Spondyloarthritis Medications Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Axial Spondyloarthritis Medications Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Axial Spondyloarthritis Medications Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Axial Spondyloarthritis Medications Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Axial Spondyloarthritis Medications Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Axial Spondyloarthritis Medications Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Axial Spondyloarthritis Medications Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Axial Spondyloarthritis Medications Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Axial Spondyloarthritis Medications Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Axial Spondyloarthritis Medications Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Axial Spondyloarthritis Medications Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Axial Spondyloarthritis Medications Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Axial Spondyloarthritis Medications Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Axial Spondyloarthritis Medications Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Axial Spondyloarthritis Medications Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Axial Spondyloarthritis Medications Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Axial Spondyloarthritis Medications Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Axial Spondyloarthritis Medications Sales (K Units) by Type (2019-2024)
 Table 51. Global Axial Spondyloarthritis Medications Sales (K Units) by Type (2025-2030)
 Table 52. Global Axial Spondyloarthritis Medications Sales Market Share by Type (2019-2024)
 Table 53. Global Axial Spondyloarthritis Medications Sales Market Share by Type (2025-2030)
 Table 54. Global Axial Spondyloarthritis Medications Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Axial Spondyloarthritis Medications Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Axial Spondyloarthritis Medications Revenue Market Share by Type (2019-2024)
 Table 57. Global Axial Spondyloarthritis Medications Revenue Market Share by Type (2025-2030)
 Table 58. Global Axial Spondyloarthritis Medications Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Axial Spondyloarthritis Medications Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Axial Spondyloarthritis Medications Sales (K Units) by Application (2019-2024)
 Table 61. Global Axial Spondyloarthritis Medications Sales (K Units) by Application (2025-2030)
 Table 62. Global Axial Spondyloarthritis Medications Sales Market Share by Application (2019-2024)
 Table 63. Global Axial Spondyloarthritis Medications Sales Market Share by Application (2025-2030)
 Table 64. Global Axial Spondyloarthritis Medications Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Axial Spondyloarthritis Medications Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Axial Spondyloarthritis Medications Revenue Market Share by Application (2019-2024)
 Table 67. Global Axial Spondyloarthritis Medications Revenue Market Share by Application (2025-2030)
 Table 68. Global Axial Spondyloarthritis Medications Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Axial Spondyloarthritis Medications Price (US$/Unit) by Application (2025-2030)
 Table 70. Bayer Company Information
 Table 71. Bayer Description and Business Overview
 Table 72. Bayer Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Bayer Axial Spondyloarthritis Medications Product
 Table 74. Bayer Recent Developments/Updates
 Table 75. Novacap Company Information
 Table 76. Novacap Description and Business Overview
 Table 77. Novacap Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Novacap Axial Spondyloarthritis Medications Product
 Table 79. Novacap Recent Developments/Updates
 Table 80. Abbott Company Information
 Table 81. Abbott Description and Business Overview
 Table 82. Abbott Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Abbott Axial Spondyloarthritis Medications Product
 Table 84. Abbott Recent Developments/Updates
 Table 85. Pfizer Company Information
 Table 86. Pfizer Description and Business Overview
 Table 87. Pfizer Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Pfizer Axial Spondyloarthritis Medications Product
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Johnson & Johnson Company Information
 Table 91. Johnson & Johnson Description and Business Overview
 Table 92. Johnson & Johnson Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Johnson & Johnson Axial Spondyloarthritis Medications Product
 Table 94. Johnson & Johnson Recent Developments/Updates
 Table 95. Cigna Company Information
 Table 96. Cigna Description and Business Overview
 Table 97. Cigna Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Cigna Axial Spondyloarthritis Medications Product
 Table 99. Cigna Recent Developments/Updates
 Table 100. Geri-Care Pharmaceuticals Company Information
 Table 101. Geri-Care Pharmaceuticals Description and Business Overview
 Table 102. Geri-Care Pharmaceuticals Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Geri-Care Pharmaceuticals Axial Spondyloarthritis Medications Product
 Table 104. Geri-Care Pharmaceuticals Recent Developments/Updates
 Table 105. Perrigo Company Company Information
 Table 106. Perrigo Company Description and Business Overview
 Table 107. Perrigo Company Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Perrigo Company Axial Spondyloarthritis Medications Product
 Table 109. Perrigo Company Recent Developments/Updates
 Table 110. Kopran Company Information
 Table 111. Kopran Description and Business Overview
 Table 112. Kopran Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Kopran Axial Spondyloarthritis Medications Product
 Table 114. Kopran Recent Developments/Updates
 Table 115. Merck Sharp & Dohme Company Information
 Table 116. Merck Sharp & Dohme Description and Business Overview
 Table 117. Merck Sharp & Dohme Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Merck Sharp & Dohme Axial Spondyloarthritis Medications Product
 Table 119. Merck Sharp & Dohme Recent Developments/Updates
 Table 120. Sun Pharmaceutical Industries Company Information
 Table 121. Sun Pharmaceutical Industries Description and Business Overview
 Table 122. Sun Pharmaceutical Industries Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. Sun Pharmaceutical Industries Axial Spondyloarthritis Medications Product
 Table 124. Sun Pharmaceutical Industries Recent Developments/Updates
 Table 125. GlaxoSmithKline Company Information
 Table 126. GlaxoSmithKline Description and Business Overview
 Table 127. GlaxoSmithKline Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. GlaxoSmithKline Axial Spondyloarthritis Medications Product
 Table 129. GlaxoSmithKline Recent Developments/Updates
 Table 130. Reddy Pharmaceuticals Company Information
 Table 131. Reddy Pharmaceuticals Description and Business Overview
 Table 132. Reddy Pharmaceuticals Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 133. Reddy Pharmaceuticals Axial Spondyloarthritis Medications Product
 Table 134. Reddy Pharmaceuticals Recent Developments/Updates
 Table 135. Verywell Company Information
 Table 136. Verywell Description and Business Overview
 Table 137. Verywell Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 138. Verywell Axial Spondyloarthritis Medications Product
 Table 139. Verywell Recent Developments/Updates
 Table 140. UCB Company Information
 Table 141. UCB Description and Business Overview
 Table 142. UCB Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 143. UCB Axial Spondyloarthritis Medications Product
 Table 144. UCB Recent Developments/Updates
 Table 145. Novartis Company Information
 Table 146. Novartis Description and Business Overview
 Table 147. Novartis Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 148. Novartis Axial Spondyloarthritis Medications Product
 Table 149. Novartis Recent Developments/Updates
 Table 150. Eli Lilly and Co. Company Information
 Table 151. Eli Lilly and Co. Description and Business Overview
 Table 152. Eli Lilly and Co. Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 153. Eli Lilly and Co. Axial Spondyloarthritis Medications Product
 Table 154. Eli Lilly and Co. Recent Developments/Updates
 Table 155. AstraZeneca Company Information
 Table 156. AstraZeneca Description and Business Overview
 Table 157. AstraZeneca Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 158. AstraZeneca Axial Spondyloarthritis Medications Product
 Table 159. AstraZeneca Recent Developments/Updates
 Table 160. DICE Therapeutics Company Information
 Table 161. DICE Therapeutics Description and Business Overview
 Table 162. DICE Therapeutics Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 163. DICE Therapeutics Axial Spondyloarthritis Medications Product
 Table 164. DICE Therapeutics Recent Developments/Updates
 Table 165. Key Raw Materials Lists
 Table 166. Raw Materials Key Suppliers Lists
 Table 167. Axial Spondyloarthritis Medications Distributors List
 Table 168. Axial Spondyloarthritis Medications Customers List
 Table 169. Axial Spondyloarthritis Medications Market Trends
 Table 170. Axial Spondyloarthritis Medications Market Drivers
 Table 171. Axial Spondyloarthritis Medications Market Challenges
 Table 172. Axial Spondyloarthritis Medications Market Restraints
 Table 173. Research Programs/Design for This Report
 Table 174. Key Data Information from Secondary Sources
 Table 175. Key Data Information from Primary Sources
 Table 176. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Axial Spondyloarthritis Medications
 Figure 2. Global Axial Spondyloarthritis Medications Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Axial Spondyloarthritis Medications Market Share by Type: 2023 & 2030
 Figure 4. Injection Product Picture
 Figure 5. Oral Product Picture
 Figure 6. Global Axial Spondyloarthritis Medications Market Value by Application (2024-2030) & (US$ Million)
 Figure 7. Global Axial Spondyloarthritis Medications Market Share by Application: 2023 & 2030
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Other
 Figure 11. Global Axial Spondyloarthritis Medications Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 12. Global Axial Spondyloarthritis Medications Market Size (2019-2030) & (US$ Million)
 Figure 13. Global Axial Spondyloarthritis Medications Sales (2019-2030) & (K Units)
 Figure 14. Global Axial Spondyloarthritis Medications Average Price (US$/Unit) & (2019-2030)
 Figure 15. Axial Spondyloarthritis Medications Report Years Considered
 Figure 16. Axial Spondyloarthritis Medications Sales Share by Manufacturers in 2023
 Figure 17. Global Axial Spondyloarthritis Medications Revenue Share by Manufacturers in 2023
 Figure 18. Global 5 and 10 Largest Axial Spondyloarthritis Medications Players: Market Share by Revenue in Axial Spondyloarthritis Medications in 2023
 Figure 19. Axial Spondyloarthritis Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 20. Global Axial Spondyloarthritis Medications Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 21. North America Axial Spondyloarthritis Medications Sales Market Share by Country (2019-2030)
 Figure 22. North America Axial Spondyloarthritis Medications Revenue Market Share by Country (2019-2030)
 Figure 23. United States Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 24. Canada Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Europe Axial Spondyloarthritis Medications Sales Market Share by Country (2019-2030)
 Figure 26. Europe Axial Spondyloarthritis Medications Revenue Market Share by Country (2019-2030)
 Figure 27. Germany Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 28. France Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. U.K. Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. Italy Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Russia Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Asia Pacific Axial Spondyloarthritis Medications Sales Market Share by Region (2019-2030)
 Figure 33. Asia Pacific Axial Spondyloarthritis Medications Revenue Market Share by Region (2019-2030)
 Figure 34. China Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. Japan Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. South Korea Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. India Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Australia Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. China Taiwan Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Southeast Asia Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Latin America Axial Spondyloarthritis Medications Sales Market Share by Country (2019-2030)
 Figure 42. Mexico Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Brazil Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Argentina Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Colombia Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Middle East and Africa Axial Spondyloarthritis Medications Sales Market Share by Country (2019-2030)
 Figure 47. Middle East and Africa Axial Spondyloarthritis Medications Revenue Market Share by Country (2019-2030)
 Figure 48. Turkey Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Saudi Arabia Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. UAE Axial Spondyloarthritis Medications Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Global Sales Market Share of Axial Spondyloarthritis Medications by Type (2019-2030)
 Figure 52. Global Revenue Market Share of Axial Spondyloarthritis Medications by Type (2019-2030)
 Figure 53. Global Axial Spondyloarthritis Medications Price (US$/Unit) by Type (2019-2030)
 Figure 54. Global Sales Market Share of Axial Spondyloarthritis Medications by Application (2019-2030)
 Figure 55. Global Revenue Market Share of Axial Spondyloarthritis Medications by Application (2019-2030)
 Figure 56. Global Axial Spondyloarthritis Medications Price (US$/Unit) by Application (2019-2030)
 Figure 57. Axial Spondyloarthritis Medications Value Chain
 Figure 58. Axial Spondyloarthritis Medications Production Process
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SIS Group of Schools

RELATED REPORTS

Global Osteoarthritis Pain Solution Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-20Y6853
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Regenerative Therapies for Osteoarthritis Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-36Y13907
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Rheumatoid Arthritis Diagnosis Tests Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19O6132
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Psoriatic Arthritis Therapeutics Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9A6304
Mon Sep 08 00:00:00 UTC 2025

Add to Cart